Venous Ethanol for Ventricular Tachycardia
A legfontosabb adatok
- Hol
- Houston (Egyesült Államok)A helyszín megnézése
- Fázis
- 2. fázis
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 85 év között vagy?
Forrás: NCT05511246: ki vehet részt
Helyszínek itt: Egyesült Államok
- Houston Methodist HospitalHouston, Egyesült ÁllamokContact: Chinwe Ngumezi, RNRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- The Methodist Hospital Research Institute
- Azonosító
- NCT05511246
- A regiszteradat frissítve
- 2026. július 24.
- Eredeti leírás
Comparative effectiveness randomized clinical trial, comparing endocardial radiofrequency ablation alone vs radiofrequency ablation combined with venous ethanol in patients with ischemic ventricular tachycardia -Venous Ethanol for Left Ventricular Ischemic Ventricular Tachycardia -VELVET clinical trialA teljes eredeti leírásKevesebb
Venous Ethanol for Ischemic Left Ventricular Tachycardia
Comparative effectiveness randomized clinical trial, comparing endocardial radiofrequency ablation alone vs radiofrequency ablation combined with venous ethanol in patients with ischemic ventricular tachycardia -Venous Ethanol for Left Ventricular Ischemic Ventricular Tachycardia -VELVET clinical trial
Bevonási feltételek: Male and female, ages of 18 and 85 years and with a prior ICD implant; Diagnosed with ischemic cardiomyopathy: Prior myocardial infarction (pathological Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause); One of the following VT events (within last 6 months): a) ≥3 episodes of VT treated with anti-tachycardia pacing (ATP) or anti-arrhythmic drugs; b) ≥1 appropriate ICD shocks; c) ≥3 VT episodes within 24 hr; d) sustained VT below detection rate of the ICD documented by EKG/cardiac monitor; Patients deemed candidates for RF ablation of VT; Able and willing to comply with pre-, post-, and follow-up requirements; Willing to sign the informed consent.
Kizáró feltételek: Disease process likely to limit survival to <12 months; New York Heart Association class IV heart failure; Cardiac surgery within the past 2 months (unless VT was incessant),; Acute coronary syndrome in the past 2 months (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on EKG); Another reversible cause of VT (e.g. electrolyte abnormalities, drug-induced arrhythmia); Covid-19 positive testing within 14 days of randomization procedure; Creatinine clearance <25 cc/min (using Cockcroft-Gault equation) except for patients on dialysis. (Contrast induced nephropathy is irrelevant in end-stage renal disease patients on dialysis, in whom the concern for contrast-induced renal dysfunction is not there since there is no chance of further kidney damage). Additionally, patients on dialysis will be excluded from the imaging sub-study; Left ventricular (LV) ejection fraction ≤10%; Mobile LV thrombus on echocardiography; Absence of vascular access to the LV; Severe aortic stenosis or mitral regurgitation with a flail leaflet; Pregnancy; Unwilling or unable to provide informed consent; Enrolled, or planning to get enrolled, in another research study during his/her participation on the Velvet trial.